{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:54:51Z","timestamp":1794351291835,"version":"4.9.0"},"reference-count":49,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,10,24]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Pure apocrine carcinoma of the breast is rare and has been defined by using a combination of morphologic (apocrine morphology in &gt;90% of tumour cells) and immunohistochemical criteria (oestrogen receptor (ER) and progesterone receptor (PR) negative and androgen receptor (AR) positive). Recent advances in the molecular classification of breast tumours have uncovered a subset of breast tumours associated with high expression of androgen receptor mRNA including the so-called \u2018luminal androgen receptor (LAR) tumours\u2019 and \u2018molecular apocrine tumours\u2019 (MATs). Recognition of these tumour subsets has opened potential avenues for therapies exploiting the AR pathway in triple negative breast carcinoma (TNBC). In this second part of our two-part review, we focus on the definition of pure apocrine carcinoma, recent advances in understanding the molecular apocrine signature in breast carcinoma, its relationship to pure apocrine carcinoma defined at the level of light microscopy and immunohistochemistry (IHC) and the therapeutic implications of androgen expression in TNBC. We complete the article with a summary of the utility of IHC in stratifying apocrine lesions of the breast.<\/jats:p>","DOI":"10.1136\/jclinpath-2018-205485","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T12:16:03Z","timestamp":1542111363000},"page":"7-11","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast"],"prefix":"10.1136","volume":"72","author":[{"given":"Clare","family":"D'Arcy","sequence":"first","affiliation":[{"name":"Histopathology, Breast Check, Irish National Breast Screening Programme and St. Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily M","family":"Quinn","sequence":"additional","affiliation":[{"name":"Histopathology, Breast Check, Irish National Breast Screening Programme and St. Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"2025112109025851000_72.1.7.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014"},{"key":"2025112109025851000_72.1.7.2","unstructured":"Lakhani SR . World health organisation classification of tumours of the breast. 4 edn. Lyon: International Agency for Research on Cancer, 2012."},{"key":"2025112109025851000_72.1.7.3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.50"},{"key":"2025112109025851000_72.1.7.4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PAS.0000000000000671","article-title":"Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2025112109025851000_72.1.7.5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208561"},{"key":"2025112109025851000_72.1.7.6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197304)31:4<793::AID-CNCR2820310406>3.0.CO;2-A"},{"key":"2025112109025851000_72.1.7.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2005.01836.x"},{"key":"2025112109025851000_72.1.7.8","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2011.088930"},{"key":"2025112109025851000_72.1.7.9","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199505000-00007"},{"key":"2025112109025851000_72.1.7.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1998.tb03948.x"},{"key":"2025112109025851000_72.1.7.11","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.301"},{"key":"2025112109025851000_72.1.7.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209415"},{"key":"2025112109025851000_72.1.7.13","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"2025112109025851000_72.1.7.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"2025112109025851000_72.1.7.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.03.016"},{"key":"2025112109025851000_72.1.7.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0915"},{"key":"2025112109025851000_72.1.7.17","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3421"},{"key":"2025112109025851000_72.1.7.18","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-546","article-title":"Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes","volume":"14","author":"Darb-Esfahani","year":"2014","journal-title":"BMC Cancer"},{"key":"2025112109025851000_72.1.7.19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.humpath.2015.05.017","article-title":"Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast","volume":"46","author":"Vranic","year":"2015","journal-title":"Hum Pathol"},{"key":"2025112109025851000_72.1.7.20","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2626"},{"key":"2025112109025851000_72.1.7.21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4132\/KoreanJPathol.2012.46.2.169","article-title":"The clinicopathologic features of molecular apocrine breast cancer","volume":"46","author":"Cha","year":"2012","journal-title":"Korean J Pathol"},{"key":"2025112109025851000_72.1.7.22","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.159"},{"key":"2025112109025851000_72.1.7.23","doi-asserted-by":"publisher","DOI":"10.1007\/BF01805738"},{"key":"2025112109025851000_72.1.7.24","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/94.4.371"},{"key":"2025112109025851000_72.1.7.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2012.11.004"},{"key":"2025112109025851000_72.1.7.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4741.2003.09422.x"},{"key":"2025112109025851000_72.1.7.27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp510"},{"key":"2025112109025851000_72.1.7.28","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.54"},{"key":"2025112109025851000_72.1.7.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2012.08.007"},{"key":"2025112109025851000_72.1.7.30","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3984-z"},{"key":"2025112109025851000_72.1.7.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9832-0"},{"key":"2025112109025851000_72.1.7.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.05.026"},{"key":"2025112109025851000_72.1.7.33","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08274"},{"key":"2025112109025851000_72.1.7.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3327"},{"key":"2025112109025851000_72.1.7.35","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.464"},{"key":"2025112109025851000_72.1.7.36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/cncr.30683","article-title":"Androgen receptor-positive, triple-negative breast cancer","volume":"123","author":"Gucalp","year":"2017","journal-title":"Cancer"},{"key":"2025112109025851000_72.1.7.37","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0406-x"},{"key":"2025112109025851000_72.1.7.38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2016.39","article-title":"Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology","volume":"29","author":"Weisman","year":"2016","journal-title":"Mod Pathol"},{"key":"2025112109025851000_72.1.7.39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.17305\/bjbms.2016.1811","article-title":"Apocrine carcinoma of the breast: a brief update on the molecular features and targetable biomarkers","volume":"17","author":"Vranic","year":"2017","journal-title":"Bosn J Basic Med Sci"},{"key":"2025112109025851000_72.1.7.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0369"},{"key":"2025112109025851000_72.1.7.41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2559.2007.02888.x","article-title":"An update on apocrine lesions of the breast","volume":"52","author":"O'Malley","year":"2008","journal-title":"Histopathology"},{"key":"2025112109025851000_72.1.7.42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.5858\/arpa.2016-0238-RA","article-title":"Atypical apocrine adenosis: diagnostic challenges and pitfalls","volume":"140","author":"Asirvatham","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2025112109025851000_72.1.7.43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-0463.2011.02840.x","article-title":"Benign apocrine papillary lesions of the breast lacking or virtually lacking myoepithelial cells-potential pitfalls in diagnosing malignancy","volume":"120","author":"Cserni","year":"2012","journal-title":"APMIS"},{"key":"2025112109025851000_72.1.7.44","first-page":"105","article-title":"Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features","volume":"110","author":"Mazoujian","year":"1983","journal-title":"Am J Pathol"},{"key":"2025112109025851000_72.1.7.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02181.x"},{"key":"2025112109025851000_72.1.7.46","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys034"},{"key":"2025112109025851000_72.1.7.47","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2001.24327"},{"key":"2025112109025851000_72.1.7.48","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.040626"},{"key":"2025112109025851000_72.1.7.49","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880004"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2018-205485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:03:18Z","timestamp":1763744598000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2018-205485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,13]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/jclinpath-2018-205485"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2018-205485","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]}}}